| Document |
Document Title |
|
WO/2023/275336A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/276813A1 |
The present invention addresses the problem of providing a pyridazinone compound which has excellent bactericidal/antibacterial activity and excellent safety, while being industrially beneficially synthesized; and an agricultural/horticu...
|
|
WO/2023/277313A1 |
The present invention relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.
|
|
WO/2023/277289A1 |
The present application provides: a heterocyclic compound; and an organic light-emitting device which comprises an organic layer containing the heterocyclic compound.
|
|
WO/2023/277446A1 |
The present specification relates to a heterocyclic compound, an organic light-emitting device comprising same, and a composition for an organic layer.
|
|
WO/2022/268119A1 |
A sulfoximine compound and a use thereof. Specifically disclosed is a compound represented by the following formula or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/267673A1 |
The present invention relates to the technical field of biomedicines, and in particular to a sulfoximide substituted indazole compound, or an isomer and pharmaceutically acceptable salt thereof. The structure of the compound is shown as ...
|
|
WO/2022/267661A1 |
The present application belongs to the field of organic materials, and relates to an organic compound, and an electronic element and an electronic device using same. The organic compound has a structure as represented by formula 1, and t...
|
|
WO/2022/270741A1 |
The present specification relates to a heterocyclic compound, an organic light-emitting device, and a composition for an organic material layer of an organic light-emitting device.
|
|
WO/2022/263800A1 |
The invention relates to a process for synthesising organic molecules. The invention provides a process for forming an sp2-sp3 carbon-carbon bond between a first compound comprising a substituted or unsubstituted aromatic group and a sec...
|
|
WO/2022/264826A1 |
The compound is represented by formula (1) below.
|
|
WO/2022/265993A1 |
This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Ka). These chemical entities are useful,...
|
|
WO/2022/264827A1 |
A compound represented by formula (1).
|
|
WO/2022/262657A1 |
The present invention relates to an N-substituted phenylsulfonamide compound and a use thereof. Specifically, the present invention provides a compound represented by formula I, or an optical isomer thereof, or a racemate thereof, or a p...
|
|
WO/2022/262691A1 |
Provided herein are heterocyclic compounds shown in Formula (I) and their pharmaceutically acceptable salts thereof suitable for inhibiting or regulating the activity of SOS1. These compounds are useful for preventing and/or treating SOS...
|
|
WO/2022/257584A1 |
The present invention relates to a compound, which has a structural formula shown in formula (I) and is suitable for use in electronic components, especially in organic electroluminescence devices, and relates to a material for organic e...
|
|
WO/2022/261473A1 |
The application relates to compounds of Formula (I) and (III), their pharmaceutically acceptable salts, and their pharmaceutical compositions. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory sy...
|
|
WO/2022/261154A1 |
The present invention provides compounds of the formula where R1, R2, R3, R4a, R4b, R4c, R5, R6, X, Y, and Z are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically ac...
|
|
WO/2022/260236A1 |
The present application provides a heterocyclic compound and an organic light-emitting device, which comprises an organic layer containing the heterocyclic compound.
|
|
WO/2022/260443A1 |
The present invention provides a novel compound and an organic light emitting device using same.
|
|
WO/2022/260096A1 |
Provided is a photoelectric conversion element material that is for an imaging element and that contributes to production of a photoelectric conversion element that is for an imaging element and that exhibits excellent dark current and e...
|
|
WO/2022/254395A1 |
The present invention relates a novel process for preparing compounds of formula (I) or salts or N-oxides thereof, Formula (I) wherein, Ra, Rb, R1, R2, R3, R4 and n are as defined in the description. The process for preparing a compound ...
|
|
WO/2022/256702A1 |
Compounds of formula I and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and m...
|
|
WO/2022/253327A1 |
Disclosed are a preparation method and use of a compound having an immunomodulatory function. Specifically, disclosed is a compound having the structure as shown in formula I, wherein the definition of each group is as described in the s...
|
|
WO/2022/253316A1 |
The present invention provides a quinoxaline derivative, preparation therefor and a use thereof. Specifically, the present invention provides a compound represented by formula (I) as shown below, or a pharmaceutically acceptable salt, en...
|
|
WO/2022/255890A1 |
The present invention provides novel compounds which bind to cereblon, and methods of use thereof. The compounds are represented by Formulas (la), (lb), (lla), (lib), (Ilia), (lllb), (IVa), (IVb), (Va), (Vb), (Via) and (Vlb).
|
|
WO/2022/254027A1 |
The present invention relates to a compound of formula (I), or a tautomer, a stereoisomer, a hydrate, a solvate, a polymorph, a prodrug, an isotope, or a co-crystal thereof, or a pharmaceutically acceptable salt thereof, wherein R1, R2, ...
|
|
WO/2022/247796A1 |
Various applications of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a stereoisomer, an isotope derivative, or a prodrug thereof as a cyclin-dependent kinase 9 (CDK9) inhibitor in the treatment o...
|
|
WO/2022/251359A1 |
The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
|
|
WO/2022/246662A1 |
The present disclosure relates to the technical field of display, and provides an organic compound and a light-emitting device. The structure of the organic compound is as represented by formula 1, formula 2 or formula 3. According to th...
|
|
WO/2022/251588A1 |
The invention provides heterobifunctional compounds, pharmaceutical compositions and their use in protein degradation and treating disease, such as cancer. The heterobifunctional compounds feature thalidomide derived moieties that binds ...
|
|
WO/2022/249113A1 |
The present invention relates to a novel compound having an activity for inhibiting binding between AIMP2-DX2 and KRAS, and a use thereof. The compound according to the present invention is useful for the prevention or treatment of disea...
|
|
WO/2022/247760A1 |
Disclosed are compounds of formulae (I) and (II) or a pharmaceutically acceptable salt, a prodrug, a tautomer or a stereoisomer thereof and a solvate thereof; and a method for preparing the compounds of formulae (I) and (II), and a pharm...
|
|
WO/2022/250228A1 |
The present specification pertains to a heterocyclic compound of chemical formula 1 and an organic light-emitting device including same.
|
|
WO/2022/247785A1 |
An application of a compound represented by formula (I) or a pharmaceutically acceptable salt, a stereoisomer, an isotopic derivative or a prodrug thereof in treating solid tumors, especially in treating liver cancer, breast cancer or pr...
|
|
WO/2022/019536A9 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/248887A1 |
The present invention relates to certain compounds that function as inhibitors of bacterial metallo-beta-lactamases. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions c...
|
|
WO/2022/244983A1 |
The present invention relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting element comprising same, methods for manufacturing same, and a composition for an organic material layer.
|
|
WO/2022/243346A1 |
The present invention relates to compounds of formula (I) wherein R1 to R3, A1 to A3 and n are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the com...
|
|
WO/2022/242147A1 |
Disclosed in the present invention are a near-infrared cyanine colorimetric fluorescent probe, a preparation method therefor and the use thereof, wherein the structural formula of the probe is as shown in formula (I). The fluorescent pro...
|
|
WO/2022/238921A1 |
Present invention relates to an in-situ and improved process for the preparation of 3-{[2-(methylsulfonyl)hydrazinyl]carbonyl}- 1-[2-oxo-2- (thiophen-2-yl)ethyl]pyridinium salts or salt-cocrystal.
|
|
WO/2022/238335A1 |
The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for...
|
|
WO/2022/237781A1 |
Provided are an amide derivative and an application thereof in medicine, in particular, an amide derivative as represented by formula (I), or a pharmaceutically acceptable salt thereof, or all stereoisomers, tautomers, and deuterated pro...
|
|
WO/2022/241257A1 |
Disclosed are compounds, methods, compositions, uses, and kits that modulate (e.g., inhibit) nicotinamide phosphoribosyltransferase (NAMPT), the production of nicotinamide mononucleotide (NMN), the production of nicotinamide adenine dinu...
|
|
WO/2022/237782A1 |
Provided are an amide derivative of formula (I), or a pharmaceutically acceptable salt thereof, or all stereoisomers, tautomers, and deuterated products thereof, and a pharmaceutical composition comprising the compound. The compound or c...
|
|
WO/2022/240876A1 |
Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I),...
|
|
WO/2022/238863A1 |
The invention refers to new quinoline-4-carboxamide derivatives, pharmaceutical compositions containing thereof and the use of the same as inhibitors of Ndc80 kinetochore subcomplex-MT binding and of kinetochore-MT binding, more preferab...
|
|
WO/2022/239919A1 |
The present specification pertains to a condensed polycyclic compound of chemical formula 1 and an organic light-emitting device including same.
|
|
WO/2022/238178A1 |
The present invention related to compounds of Formula (I) or an agronomically acceptable salt thereof, wherein X, R1, R2, R3, R4 and R6 are as described herein. The invention further relates to compositions comprising said compounds, to ...
|
|
WO/2022/232919A1 |
The present application relates to compounds, and uses thereof for example for preventing, delaying the onset or reducing the severity of, preventing or reversing the progression of, or treating a viral infection or disease. In an embodi...
|
